The central event in the pathogenesis of prion diseases is a profound confo
rmational change of the prion protein (PrP) from an alpha-helical (PrPC) to
a beta-sheet-rich isoform (PrPSc). The elucidation of the mechanism of con
formational transition has been complicated by the challenge of collecting
high-resolution biophysical data on the relatively insoluble aggregation-pr
one PrPSc isoform. In tin attempt to facilitate the structural analysis of
PrPSc, a redacted chimeric mouse-hamster PrP of 106 amino acids (MHM2 PrP10
6) with two deletions (Delta 23-88 and Delta 141-176) was expressed and pur
ified from Escherichia coli. PrP106 retains the ability to support PrPSc fo
rmation in transgenic mice, implying that it: contains all regions of PrP t
hat are necessary for the conformational transition into the pathogenic iso
form [Supattapone, S., et al. (1999) Cell 96, 869-878]. Unstructured at low
concentrations, recombinant unglycosylated PrP106 (rPrP106) undergoes a co
ncentration-dependent conformational transition to a beta-sheet-rich form.
Following the conformational transition, rPrP106 possesses properties simil
ar to those of PrP(Sc)106, such as high beta-sheet content, defined tertiar
y structure, resistance to limited digestion by proteinase K, and high ther
modynamic stability. In GdnHCl-induced denaturation studies, a single coope
rative conformational transition between the unstructured monomer and the a
ssembled beta-oligomer was observed. After proteinase K digestion, the olig
omers retain an intact core with unusually high beta-sheet content (>80%).
Using mass spectrometry, we discovered that the region of residues 134-215
of rPrP106 is protected from proteinase K digestion anti possesses a solven
t-independent propensity to adopt a beta-sheet-rich conformation. Tn contra
st to the PrP(Sc)106 purified from the brains of neurologically impaired an
imals, multimeric beta-rPrP106 remains soluble, providing opportunities for
detailed structural studies.